SCHEMBL1678573

SCHEMBL1678573

O=C(CS(=O)(=O)c1ccc2[nH]c(-c3ccc(Cl)s3)nc2c1)NCc1ccc(N2CCCCC2=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 14/20 0.60
▸ MAPT P10636 1/20 0.40
▸ LMNA P02545 3/20 0.40
▸ TSHR P16473 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ GALR3 O60755 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3864158 0.88 F10 (0.72) F10MAPTLMNATSHRHPGD
SCHEMBL3864135 0.85 F10 (0.65) F10MAPTLMNAHPGDSMN1; SMN2
SCHEMBL3872206 0.84 F10 (0.61) F10MAPTLMNATSHRHPGD
SCHEMBL3861689 0.83 F10 (0.69) F10MAPTLMNAHPGDSMN1; SMN2
SCHEMBL3867575 0.83 F10 (0.64) F10MAPTLMNATSHRHPGD
SCHEMBL3866715 0.80 F10 (0.88) F10
SCHEMBL3862576 0.79 F10 (0.70) F10
SCHEMBL3864129 0.79 F10 (0.59) F10MAPTLMNASMN1; SMN2L3MBTL1
SCHEMBL3866098 0.79 F10 (0.88) F10
SCHEMBL3867405 0.78 F10 (0.66) F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4668614-B2 — — 2011-04-13 — — JP claimed
EP-1558247-B1 BENZIMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2008-02-20 — — EP claimed
JP-2006500369-A — — 2006-01-05 — — JP claimed
US-20050272740-A1 Benzimidazole derivatives MERCK PATENT GMBH (DE) 2005-12-08 — — US claimed
CN-1674893-A Benzimidazole derivatives MERCK PATENT GMBH (DE) 2005-09-28 — — CN claimed
EP-1558247-A1 BENZIMIDAZOLE DERIVATIVES MERCK PATENT GmbH (DE) 2005-08-03 — — EP claimed
WO-2004017963-A1 BENZIMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2004-03-04 — — WO claimed
US-7566789-B2 Benzimidazole derivatives MERCK PATENT GMBH (DE) 2009-07-28 — — US disclosed
EP-1558247-B1 BENZIMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2008-02-20 — — EP disclosed
US-20050272740-A1 Benzimidazole derivatives MERCK PATENT GMBH (DE) 2005-12-08 — — US disclosed
CN-1674893-A Benzimidazole derivatives MERCK PATENT GMBH (DE) 2005-09-28 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272740-A1 Benzimidazole derivatives F12, F11, SERPINC1 F10 5/4885MAPT 4675/4885LMNA 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback